Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data show that imatinib treatment may promote the development of anti-leukemia...
Guardado en:
Autores principales: | Peter S Kim, Peter P Lee, Doron Levy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7808c811147148829caaa39e2e938d5c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bosutinib in the management of chronic myelogenous leukemia
por: Keller-von Amsberg G, et al.
Publicado: (2013) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
por: Harnicar S, et al.
Publicado: (2014) -
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
por: Maiko Matsushita
Publicado: (2021) -
Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML).
por: Young Kwang Chae, et al.
Publicado: (2008) -
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells
por: Yan Xu, et al.
Publicado: (2018)